FIG. 6.
NS-gEnull vaccination cross-protects against HSV-2(2.12) challenge at 105 PFU. (A) Mice were monitored for survival (P < 0.05). (B) Inoculation site disease (P > 0.05 on day 1; P = 0.01, P = 0.03, and P = 0.001 on days 5 to 7, respectively). (C) Zosteriform disease (P > 0.05 on days 3 and 4; P = 0.01, P = 0.02, and P = 0.005 on days 5 to 7, respectively). There were five mice in each group. Data points in panels B and C are means ± SEMs. (D) One year after challenge, explant cultures of DRG were monitored for virus reactivation.